Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070257 | 1.00 | HCAR2 (0.42) | HCAR2GAASMN1; SMN2ATMALOX5 | |
| SCHEMBL7071843 | 0.89 | ATM (0.52) | HCAR2SMN1; SMN2ATMALDH1A1TSHR | |
| SCHEMBL7071839 | 0.89 | ATM (0.52) | HCAR2SMN1; SMN2ATMALDH1A1TSHR | |
| SCHEMBL7074062 | 0.84 | HCAR2 (0.42) | HCAR2GAASMN1; SMN2ATMALOX5 | |
| SCHEMBL7071569 | 0.83 | NPSR1 (0.42) | HCAR2GAASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7071574 | 0.83 | NPSR1 (0.42) | HCAR2GAASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7073650 | 0.82 | HCAR2 (0.41) | HCAR2GAASMN1; SMN2ATMALOX5 | |
| SCHEMBL7073648 | 0.82 | HCAR2 (0.41) | HCAR2GAASMN1; SMN2ATMALOX5 | |
| SCHEMBL7068385 | 0.79 | ATM (0.46) | HCAR2GAASMN1; SMN2ATMALDH1A1 | |
| SCHEMBL1879216 | 0.79 | HCAR2 (0.61) | HCAR2ATMALOX5ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | claimed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | claimed |
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | HCAR2 672/4885GAA 3453/4885SMN1; SMN2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.